Arginine phosphorylation (pArg) is recently discovered as a ubiquitous protein N-phosphorylation in bacteria. However, its prevalence and roles in mammalian cells remain largely unknown due to the lack of established workflow and the inherent lability of phosphoramidate (P-N) bond. Emerging evidences suggest that N-phosphorylation may extensively exist in eukaryotes and play crucial roles. We report a phosphoproteomic workflow, which allows for the first time revealing the widespread occurrence of pArg in human cells by mass spectrometry. By virtue of this approach, we identified 152 high-confidence pArg sites derived from 118 proteins. Remarkably, the discovered pArg phosphorylation motif and gene ontology hint a possible cellular function of arginine phosphorylation which may regulate the favorability of propeptide convertase substrate. The obtained pArg dataset paves a way for a better understanding of the biological functions of eukaryotic pArg in the future. protein arginine phosphorylation, N-phosphorylation, proteomics, mass spectrometry, human cells Citation:
Introduction
Protein reversible phosphorylation is a ubiquitous and dynamic post-translational modification (PTM) involving almost all aspects of cellular regulation [1] [2] [3] . For decades, extensive studies are focused on O-phosphorylation taking place on serine, threonine and tyrosine residues, while Nphosphorylations on arginine, histidine and lysine have long been underestimated due to the intrinsic instability of phosphoramidate [4, 5] . Lagging behind the striking discoveries of histidine phosphorylation in mammalian cells [6] , the study of arginine phosphorylation (pArg) has just begun and is restricted to prokaryotic cells. Recent breakthrough studies shed light on pArg participating in DNA transcription regulation and protein degradation in gram-positive bacteria [7] [8] [9] . Although he presence of pArg in vertebrates is sporadically reported, such as on histone H3 [10, 11] , histone H4 [12] , and myelin basic protein (MBP) [13] , its prevalence and roles in eukaryotes remain largely unknown, mainly due to the limited research tools and the lack of appropriate largescale workflow for identification.
The large-scale discovery of mammalian pArg has been hindered by several issues. First, the intrinsic nature of P-N bond in pArg makes it unstable to heat and acid [14] . Consequently, the conventional proteomic protocols involving strong acidic conditions optimized for O-phosphorylation are not suitable. Second, since mammalian pArg kinase and phosphatase have not yet been discovered, the strategies used for transiently increase prokaryotic pArg levels, such as heatshock treatment and knock-out of pArg phosphatase, are not applicable for mammalian cells [14] . The lack of a sufficient number of identified mammalian pArg proteins results in the inability to predict phosphorylation motif by bioinformatics, which in turn hinders the identification of kinases. Third, as a PTM, pArg level may vary in different cells. Unfortunately, there are no precedents for guiding the choice of appropriate mammalian cell lines. Therefore, there is an urgent need for a workflow suitable for identifying mammalian pArg proteins in large-scale.
Here, we report the discovery of pArg in human cells by using a new proteomic workflow. Crucially, 118 high-confidence pArg proteins are identified and they fall into several specific protein classes participated in DNA/RNA associated process. The deduced pArg motif has laid the foundation for the identification of pArg kinase and phosphatase. Strikingly, a pArg site was found in the vital cleavage region of proglucagon (PG), suggesting that pArg may be involved in the regulation of the substrate favorability of prohormone convertase (PC). The systematic discovery of human pArg proteins not only clarified the long-standing question of whether pArg exists in eukaryotes, but also provided insights into its biological studies in the future.
Results and discussion

pArg level exhibits variability in different cell lines
To choose a suitable model cell line, we first analyzed the total pArg content in human cell lines with home-made panspecific pArg antibody [15] . The specificity of pArg antibody and its applicability for complex samples were validated using Bacillus subtilis and Bacillus licheniformis lysates ( Figure S1 , Supporting Information online). Thereafter, Western blot assay was applied to four human cell lysates. As a result, we found that Jurkat cells showed a different band pattern among four cell lines ( Figure S2 ). Specifically, several high-intensity bands were significantly reduced or eliminated after acid-treatment ( Figure 1 ). In consideration of signal intensity and protein diversity, we chose Jurkat cells as a model for the following proteomics study.
Optimal sample preparation and MS parameters increases the number of identified pArg sites
Encouraged by the direct detection of pArg proteins by Western blotting, we set out to explore the prevalence of pArg in Jurkat cells by mass spectrometry. In general, the large-scale identification and precise localization of labile Nphosphorylation sites greatly rely on proper sample preparation approach and appropriate MS fragmentation mode [16] . Also, the enrichment of phosphopeptide is crucial for all sub-stoichiometric PTMs. However, an insurmountable obstacle is the acid lability of pArg, since the acidic condition is typically considered as a necessity for better LC separation and precursor ionization. Moreover, the sequence discrimination caused by enrichment also needs to be considered, as any statistically serious deviation from the physiological sequence distribution will affect the deduction of pArg motif. Accordingly, we adopted the reported mildacidic TiO 2 -based enrichment method [14] as a blueprint and designed an improved workflow (detailed in Table S1 , Supporting Information online).
The entire proteomic workflow was optimized in several aspects to extend the coverage of phosphopeptides while preserving labile pArg (Figure 2(a) ). These included (1) treatment with a broad-spectrum phosphatase inhibitor in prior to cell lysis, (2) inactivation of endogenous phosphatase with a strong denaturant, (3) removal of small-molecule interferences by acetone precipitation, (4) control of temperature and shortening sample processing time, (5) shorten Western blotting analysis of Jurkat cell lysate by using panspecific pArg antibody and Ponceau staining. As a control, the lysates were treated with 0.2 N HCl at 30°C for 1 h or blotted in the presence of pArg analog. Bands with markedly reduced intensity after HCl-treatment are indicated by red asterisks. The blot was slightly overexposed to show the difference clearly. The purpose of acid-treatment is mainly to show the difference before and after the treatment. Of note, prolonged acid-treatment was avoided which can precipitate eukaryotic proteins for an unknown reason (color online).
the TiO 2 enrichment process, (6) use of volatile eluent to avoid extra off-or on-line desalting steps, (7) screen of MS fragmentation mode and relevant parameters.
As a result, these optimizations substantially increased the number of identified pArg sites. As shown in Figure 2 (b), compared to the standard FASP method [17] , acetone precipitation following Urea-based cell lysis increased the number of identified pArg proteins and peptides from 161 and 192 to 245 and 307. Pre-treatment of cells with sodium per-vanadate (condition vi) further boosted the identities to 420 and 565 ( Figure 2(c) ). Presumably, per-vanadate serving as a covalent phosphatase inhibitor is more potent than Na 3 VO 4 or pAIE (competitive inhibitor). Furthermore, we compared three MS 2 fragmentation modes and six parameters setting (Table S2 , condition I-IV), including collision-induced dissociation (CID) (condition II), the combination of electron-transfer dissociation (ETD) and higher-energy CID (EThcD) (III-V), and neural loss triggered EThcD (I, VI). As shown in Figure 2 (d), condition I, II and III produced the greatest number of identification and the highest cross-correlation score (Xcorr) in the respective mode. Accordingly, two biological replicates from each condition I, II and III, were combined as a "union dataset" for data analysis.
pArg widespread exists in human cells
We finally identified 817 pArg sites of 730 peptides derived from 500 proteins in Jurkat cells, demonstrating the widespread occurrence of pArg in human cells. Meanwhile, the TiO 2 -based enrichment allowed us to analyze O-and N-phosphorylation species simultaneously. In general, the pervanadate treatment improved the identification of all six phosphorylation forms ( Figure S3 ). Phosphopeptides accounted for about 2/3 of eluted peptides, indicating good selectivity of enrichment procedure ( Figure S3 , Excel S1, Supporting Information online). Of note, pArg proteins only showed limited over-lapping with pHis and pLys (Figure 2 (e)). The ptmRS distribution of pArg was similar to that of pHis and pLys ( Figure S4 ), but the proportion of high-confidence category (ptmRS≥75) was lower than that of Ophosphorylation ( Figure S5 ). This was presumably due to the fact that phosphoramidate is more susceptible to neutral loss than phosphoester in the gas-phase [18, 19] . Although ptmRS>99 is used as a standard setting for O-phosphorylation site mapping, we reduced it to 75, according to the reported site-mapping protocols used for bacterial N-phosphorylation [16, 18] . In the previous literature, more than 50% of verified bacterial N-phosphorylation sites have a ptmRS less than 75 or even less than 50. In general, reduction of ptmRS to 75 in PhosphoRS software would increase the FLR from converged zero to about 1%, but it will greatly increase the identity number at an acceptable cost [20, 21] . To further verify the credibility of our data processing approach, we applied it to a recently released E. coli proteomic dataset reporting 246 pHis sites [16] . E. coli as a Gram-negative strain does not contain pArg and can therefore be used as a negative control for pArg site mapping parameters. As a result, only two ambiguous pArg sites were identified from the E. coli negative control dataset when ptmRS was set to 75. In addition, the total number and the relative ratio of Ophosphorylated proteins identified in Jurkat samples using ptmRS≥75 as a filter were comparable with the literature [22, 23] , and three N-phosphorylation forms showed a limited overlapping with each other. Taken together, the 152 highconfidence pArg sites identified by our workflow were statistically reliable (Excel S2).
Human pArg proteins enrich in certain protein classes
Gene ontology (GO) analysis was then performed to elucidate the potential association of pArg with their physiological functions. Briefly, the "union dataset" was searched with SEQUEST and peptide hits with a C-terminal pArg site were excluded because they are less likely to be cleavable by trypsin [24] . After manual checking of all spectrum, 118 pArg proteins were subjected to GO analysis. Protein classification revealed that pArg proteins were abundantly enriched in the group of "nucleic acid binding", alongside with a moderate enrichment in the group of "transcription factor", "hydrolase", "enzyme modulator", "chaperone" and "membrane traffic protein" (Figure 3(a) ). Strikingly, the first and the only well-studied prokaryotic pArg protein CtsR is also a transcription repressor regulating gene expression through binding to DNA. Upon phosphorylation on Arg residues, CtsR is impaired by converting the positive-charged DNA binding domain to negative. Although the same pArg "switch" may exist in eukaryotic transcriptional regulation, to our knowledge, our finding is the first evidence supporting this hypothesis.
Further bioinformatics analysis pinpointed that pArg proteins predominantly correlated with "mRNA associated process", such as "mRNA splicing and processing", "mRNA exporting from nucleus" and "termination of RNA polymerase II transcription" (Figure 3(b) , Figure S6 , Excel S3). This result differs from the observations in Gram-positive bacteria, where pArg is mainly associated with protein synthesis/degradation and metabolic functions [9, 14] .
In addition, the cellular localization of human pArg proteins was consistent with their biological processes, showing an enrichment in the nucleus. Moreover, pArg exhibited some similarities to pLys in terms of biological process and localization ( Figures S7-S10) . In contrary to pHis and pLys, pArg sites were exclusively present in certain protein kinases, implying its potential biological functions associated with kinases.
Here, the cellular location of pHis proteins can be used as control to assess the credibility of our MS data. The pHis protein localization (in both nucleoplasm and cytosol) obtained by our MS workflow was consistent with the results revealed by immune-fluorescence staining in HeLa cell [6, 27] , further demonstrating the credibility of our data analysis.
Human pArg has conserved phosphorylation motifs
Importantly, human pArg possessed consensus phosphorylation motifs which were not observed in prokaryotes. The statistical analysis on 141 high-confidence pArg sequences yielded 8 degenerated sequons (Figure 3(c) ), and 4 of them have an enrichment factor greater than 10, relative to human proteome as a background. In particular, Ser and Pro were high-frequently occurred and conserved at specific sites in 7 of 8 motifs. Notably, motif RXRSXS, RRXS, and RRXXS with a match of 23, 26 and 20 pArg peptides, respectively, were also the substrate motif of Akt, PKA, and ZIP kinase [28] . The adjacent pS and pR sites may suggest a potential crosstalk between classical O-phosphorylation and non-canonical pArg N-phosphorylation, which needs for further investions.
Proglucagon possesses a pArg site located in its vital motif for processing
The paired basic amino acid in pArg motifs, such as RR and KR, is reminiscent of the substrate sequence of propeptide convertase (PC), which functions in the proteolytic activation of proglucagon (PG). Physiologically, peptides cleaved from PG play key roles in blood glucose regulation. This processing is initiated by PC-1 cleaving PG between K 90 R 91 interdomain and H 92 residue, resulting in Glicentin (Gli), major PG fragment (MPGF), GLP-1 and GLP-2 (Figure 4 (c)) [29, 30] . Remarkably, peptide pR 91 HDEFER 97 derived from PG was repeatedly detected across our MS experiments.
Since PG have significant biological relevance and K 90 R 91 interdomain is required for the substrate recognition by PC-1, the site mapping of PG was carefully performed in several ways. As shown in Figure 4(a, b) Figure S13 ) under the same condition. As shown in Figures S14 and S15, (1) the y 6 ion (pH 92 DEFER 97 ) assigning to pH 92 , (2) the characteristic pH is neutral loss triplet peaks reported in literature [31] , (3) pH is diagnostic immonium ion (m/z=190.037) reported recently [16] were exclusively detectable in the synthetic peptide, but all these characteristics were absent in the cell lysate sample. Biochemically, we immunoprecipitated endogenous PG from Jurkat cell lysate and blotted it with pArg and pHis antibody [15, 32] . As illustrated in Figure 4(d) , no signal was detected by the pHis antibody. In contrast, pArg antibody gave signal, which can be abolished by competition with pAIE, an analog of pArg. Taken together, the phosphorylation site of PG was unambiguously assigned to R 91 by MS and biochemical validation.
Conclusions
Although the widespread occurrence of arginine phosphorylation and its biological relevance have already been elucidated in gram-positive bacteria, revealing it in more complex mammalian cells remains challenging. When our manuscript was under revision, the first crystal structure of Immunoprecipitated PG is probed with either anti-pHis or anti-pArg antibody. In the competition assay, the antibody is first incubated with synthesized pPye or pAIE followed by conventional WB (color online). bacterial pArg kinase McsB is reported, 10 years after its discovery [33] . To promote the study of mammalian pArg functions, several crucial bottle-necks still need to be overcome, that includes (1) development of solid-phase peptide synthesis for pArg peptides; (2) generation of sequencespecific pArg antibodies; (3) identification of mammalian pArg kinase and phosphatase; (4) determination of pArg stoichiometry in various cell lines and its relationship with other classical O-phosphorylation species; (5) comparison of the pArg levels between physiological and pathological conditions in cells and tissues.
In summary, we report a new analytical pipeline for pArg proteins, including antibody-based cell line screening, optimized proteomics workflow, and analog-based competition assay. By virtue of this workflow, we revealed, for the first time, the widespread occurrence of pArg in human cells and its phosphorylation motif. This breaking through discovery will open up a new field for the study of eukaryotic protein post-translational modification. We envision that our analytical workflow together with the identified pArg proteins, are expected to serve as a starting point for chemical biologists and biochemists to enhance the studies of mammalian Nphosphorylation, a field with enormous challenges and promising prospects.
